title: Ofatumumab in the treatment of non-Hodgkin's lymphomas.
abstract: BACKGROUND
  Ofatumumab is a second-generation humanized monoclonal antibody targeting CD20 registered for the treatment of patients with relapsing/refractory chronic lymphocytic leukemia. This review will describe the activity of ofatumumab in patients with CD20 B-cell lymphomas.
  
  
  METHODS
  A review of all manuscript published on ofatumumab activity in B-cell lymphomas is presented with conclusions on the future use of this antibody in these patients.
  
  
  CONCLUSIONS
  Ofatumumab activity is low in indolent or aggressive B-cell lymphomas. The future of this drug is challenged by new monoclonal antibodies and new targeted drugs.
authors.affiliation: Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Hematology Department , 165, Chemin du Grand Revoyet 69495 Pierre-Benite , France +33 478864301 ; +33 478864355 ; bertrand.coiffier@univ-lyon1.fr.
authors.forename: Lionel
authors.initials: L
authors.lastname: Karlin
authors.forename: Bertrand
authors.initials: B
authors.lastname: Coiffier
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018951:Antigens, CD20 / Q000276:immunology; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018951:Antigens, CD20; D000970:Antineoplastic Agents; C527517:ofatumumab
keywords: diffuse large B-cell lymphoma; follicular lymphoma; ofatumumab